Results 31 to 40 of about 11,617 (148)

Visual acuity is reduced with increasing central retinal thickness, but also with higher age and female sex in diabetic macular oedema

Acta Ophthalmologica, EarlyView.
Abstract Introduction The increasing number of patients with diabetes has increased the incidence of diabetic macular oedema (DME) with the accompanying risk of developing visual loss. The purpose of the present study was to describe the contributions of increased central retinal thickness (CRT) and other risk factors to the reduction in visual acuity ...
Signe Krejberg Jeppesen, Toke Bek
wiley   +1 more source

Plain language summary of publication of the 96-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edema

Therapeutic Advances in Ophthalmology
Summary What is this summary about? This is a summary of a publication about the 2-year (96-week) results from the PHOTON study, which was published in Ophthalmology . Diabetic macular edema (DME) is a leading cause of vision loss in people with diabetes.
Diana V. Do, Charles C. Wykoff, Sobha Sivaprasad, David M. Brown, David S. Boyer, Taiji Sakamoto, Peter Win, Sunir Joshi, Hani Salehi-Had, András Seres, Sergio Leal, Robert Vitti, Karen W. Chu, Kimberly Reed, Yenchieh Cheng, Rafia Bhore, Zhanying Bai, Ursula Schmidt-Ott, Thomas Schmelter, Andrea Schulze, Zoran Hasanbasic, Peter J. Morgan-Warren, Xin Zhang, Alyson J. Berliner   +23 more
doaj   +1 more source

Cost-effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration and its Subtypes from the Societal and Patient Perspectives in Japan

Ophthalmology and Therapy
Introduction This study evaluated the cost-effectiveness of anti-vascular endothelial growth factor (VEGF) therapies for subtypes of neovascular age-related macular degeneration (nAMD) from the societal perspective, and for any nAMD from the patient ...
Yasuo Yanagi, Kanji Takahashi, Tomohiro Iida, Fumi Gomi, Hiroshi Onishi, Junko Morii, Taiji Sakamoto   +6 more
doaj   +1 more source

Comparative study between ranibizumab and aflibercept in the management of macular edema caused by diabetes mellitus in age group more than 40 years

Al-Azhar Assiut Medical Journal, 2019
Background Diabetic macular edema (DME) is a common cause of blindness and visual impairment in diabetic patients, which can affect the quality of life.
Abd El-Magid M Tag El-Din
doaj   +1 more source

Intravitreal Aflibercept as a Rescue Therapy for Retinal Neovascularization and Macular Edema due to Eales Disease

Case Reports in Ophthalmological Medicine, 2021
We report the rescue effect of intravitreal aflibercept injections on retinal neovascularization and macular edema due to Eales disease. Case 1 was a 36-year-old female. Intravitreal aflibercept was administered as rescue therapy after persistent retinal
Ning-Yi Hsia, Chun-Ju Lin, Chun-Ting Lai, Henry Bair, Cheng-Hsien Chang, Jane-Ming Lin, Yi-Yu Tsai   +6 more
doaj   +1 more source

Ocular Manifestations of Metabolic Syndrome: A Systemic Vascular Phenotype

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Context Metabolic syndrome (MetS) is defined by central obesity, insulin resistance, hypertension and dyslipidemia. MetS affects over one‐third of US adults. Beyond its cardiovascular burden, MetS has clinically relevant associations with ocular health and may contribute to a systemic vascular and neuro‐metabolic phenotype involving the retina,
Ron T. Varghese, Ansu A. John
wiley   +1 more source

Radiomics Analysis for Predicting Medication‐Related Osteonecrosis of the Jaw Using Computed Tomography

Oral Diseases, EarlyView.
ABSTRACT Objectives To determine whether pretreatment radiomics can predict medication‐related osteonecrosis of the jaw (MRONJ). Methods Patients with mandibular MRONJ at Hiroshima University Hospital (2009–2024) who underwent MDCT before initiating bone resorption inhibitors were retrospectively identified. Records from 2009 to 2020 were also reviewed
Masaru Konishi
wiley   +1 more source

Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context

BMC Ophthalmology, 2018
Background To compare anti-VEGF treatments for macular disease in terms of costs and clinical outcomes. Methods We identified patients suffering from macular disease and treated either with aflibercept, ranibizumab or both at the largest public eye ...
Martin K. Schmid, Oliver Reich, Eva Blozik, Livia Faes, Nicolas S. Bodmer, Silvan Locher, Michael A. Thiel, Roland Rapold, Maximilian Kuhn, Lucas M. Bachmann   +9 more
doaj   +1 more source

Plasma PlGF as a Potential Biomarker in Ramucirumab‐Based Second‐Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial

International Journal of Cancer, Volume 159, Issue 7, Page 1817-1828, 1 October 2026.
Antiangiogenic treatment with ramucirumab is a standard second‐line option in advanced gastric and gastroesophageal junction adenocarcinoma. However, reliable biomarkers are currently lacking. This exploratory biomarker analysis of the RAMIRIS trial suggests that elevated baseline and early on‐treatment levels of the pro‐angiogenic placental growth ...
Jurek Hille, Sylvie Lorenzen, Claudia Pauligk, Victoria Gensch, Peter Thuss‐Patience, Eray Goekkurt, Thomas Ettrich, Florian Lordick, Carsten Bokemeyer, Christian Müller, Peter Reichardt, Martin Sökler, Daniel Pink, Stefan Probst, Thorsten O. Goetze, Salah E. Al‐Batran, Sonja Loges, Melanie Janning   +17 more
wiley   +1 more source

Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion

Clinical Ophthalmology, 2017
Mizuki Tagami, Ryuto Sai, Masahide Fukuda, Atsushi Azumi Ophthalmology Department, Eye Center, Kobe Kaisei Hospital, Kobe, Hyogo, Japan Purpose: This study was conducted to investigate the outcome of switching therapy from ranibizumab to aflibercept in
Tagami M, Sai R, Fukuda M, Azumi A
doaj